Attached files

file filename
EX-31.2 - EX-31.2 - CLS Holdings USA, Inc.ex31-2.htm
EX-32.1 - EX-32.1 - CLS Holdings USA, Inc.ex32-1.htm
EX-31.1 - EX-31.1 - CLS Holdings USA, Inc.ex31-1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 

 
FORM 10-Q
 

 
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended August 31, 2015
 
or
 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
 
Commission File Number: 333-174705
 
CLS HOLDINGS USA, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
27-3369810
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)

1435 Yarmouth Street, Boulder, Colorado 80304
(Address of principal executive offices) (Zip Code)

(888) 438-9132
Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x    No o
  
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x    No o
  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer o
Accelerated filer o
Non-accelerated filer o
Smaller reporting company x
(Do not check if a smaller reporting company)
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o    No x
 
State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: 20,060,003 shares (post reverse-split) of $0.0001 par value common stock outstanding as of October 09, 2015.   
 
 
CLS HOLDINGS USA, INC.

FORM 10-Q
Quarterly Period Ended August 31, 2015
 
TABLE OF CONTENTS
 
 
Page
   
  3
   
PART I. FINANCIAL INFORMATION
 
Item 1.
  4
 
  4
 
  5
 
  7
 
  8
Item 2.
  15
Item 3.
18
Item 4.
18
   
PART II. OTHER INFORMATION
 
Item 1.
19
Item 1A.
 19
Item 2.
 19
Item 3.
 19
Item 4.
19
Item 5.
19
Item 6.
19
   
  20
 
 
EXPLANATORY NOTE
 
Unless otherwise noted, references in this registration statement to “CLS Holdings USA, Inc.,” the “Company,” “we,” “our” or “us” means CLS Holdings USA, Inc. and its subsidiaries.
 
FORWARD-LOOKING STATEMENTS
 
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. These forward-looking statements include, but are not limited to, statements relating to the adequacy of our capital to finance our planned operations, market acceptance of our services and product offerings, our ability to attract and retain key personnel, and our ability to protect our intellectual property. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology.
 
These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.
 
We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered together with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
 
AVAILABLE INFORMATION
 
We file annual, quarterly and special reports and other information with the SEC that can be inspected and copied at the public reference facility maintained by the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549-0405. Information regarding the public reference facilities may be obtained from the SEC by telephoning 1-800-SEC-0330. The Company’s filings are also available through the SEC’s Electronic Data Gathering Analysis and Retrieval System which is publicly available through the SEC’s website (www.sec.gov). Copies of such materials may also be obtained by mail from the public reference section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549-0405 at prescribed rates.
 
 
PART I – FINANCIAL INFORMATION
 
Item 1. Financial Statements.
 
CLS HOLDINGS USA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
 
   
August 31,
   
May 31,
 
   
2015
   
2015
 
             
ASSETS
           
Current assets
           
Cash and cash equivalents
 
$
61,240
   
$
208,821
 
Prepaid expenses
   
19,466
     
31,800
 
Note receivable, related party, current, net of allowance of $100,000 and $100,000
   
-
     
-
 
Total current assets
   
80,706
     
240,621
 
                 
Security deposit
   
50,000
     
50,000
 
Property, plant and equipment, net of accumulated depreciation of $223 and $0
   
2,451
     
-
 
Note receivable related party, noncurrent, net of allowance of $400,000 and $400,000
   
-
     
-
 
Intangible assets, net of accumulated amortization of $72 and $0
   
2,086
     
2,158
 
Total assets
 
$
135,243
   
$
292,779
 
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
Current liabilities
               
Accounts payable and accrued liabilities
 
$
196,082
   
$
145,024
 
Accrued compensation, related party
   
137,500
     
106,250
 
Due to related party
   
17,930
     
18,455
 
Accrued interest
   
10,192
     
2,630
 
Accrued interest, related party
   
12,789
     
3,337
 
Notes payable, related party
   
750,000
     
600,000
 
Total current liabilities
   
1,124,493
     
875,696
 
                 
Noncurrent liabilities
               
Convertible notes payable, net of debt discount of $177,778 and $194,444
   
22,222
     
5,556
 
Total Liabilities
   
1,146,715
     
881,252
 
                 
Commitments and contingencies
   
-
     
-
 
                 
Stockholder's equity
               
Common stock, $0.0001 par value; 250,000,000 shares authorized; 20,060,003
and 20,000,003 shares issued and outstanding at August 31, 2015 and
May 31, 2015
   
2,006
     
2,000
 
Additional paid-in capital
   
932,879
     
887,614
 
Stock payable
   
45,742
     
37,500
 
Accumulated deficit
   
(1,992,099
)
   
(1,515,587
)
Total stockholder's equity
   
(1,011,472
)
   
(588,473
)
                 
Total liabilities and stockholders' equity
 
$
135,243
   
$
292,779
 
 
See accompanying notes to these financial statements.
 

CLS HOLDINGS USA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

   
For the Three
   
For the Three
 
   
Months Ended
   
Months Ended
 
   
August 31,
   
August 31,
 
   
2015
   
2014
 
             
             
Revenue
 
$
-
   
$
-
 
Cost of goods sold
   
-
     
-
 
Gross margin
   
-
     
-
 
                 
Selling, general and administrative expenses
   
184,407
     
94,020
 
Professional fees
   
258,154
     
28,076
 
Total operating expenses
   
442,561
     
122,096
 
                 
Operating loss
   
(442,561
)
   
(122,096
)
                 
Other (income) expense:
               
Interest expense
   
33,951
     
-
 
Total other expense
   
33,951
     
-
 
                 
Income (Loss) before income taxes
   
(476,512
)
   
(122,096
)
                 
Income tax expense
   
-
     
-
 
                 
Net income (loss)
 
$
(476,512
)
 
$
(122,096
)
                 
Net income (loss) per share - basic
 
$
(0.02
)
 
$
(0.01
)
                 
Net income (loss) per share - diluted
 
$
(0.02
)
 
$
(0.01
)
                 
Weighted average shares outstanding - basic
   
20,001,960
     
15,000,000
 
                 
Weighted average shares outstanding - diluted
   
20,001,960
     
15,000,000
 
 
See accompanying notes to these financial statements.
 
 
CLS HOLDINGS USA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

   
For the Three
   
For the Three
 
   
Months Ended
   
Months Ended
 
   
August 31,
   
August 31,
 
   
2015
   
2014
 
CASH FLOWS FROM OPERATING ACTIVITIES
           
Net income (loss)
 
$
(476,512
)
 
$
(122,096
)
Adjustments to reconcile net loss to net cash used in operating activities:
               
Imputed interest
   
271
     
-
 
Issuance of stock for services
   
25,950
     
-
 
Stock-based compensation
   
27,292
     
-
 
Amortization of debt discount
   
16,666
     
-
 
Depreciation and amortization
   
295
     
-
 
Changes in assets and liabilities:
               
Prepaid expenses
   
12,334
     
(5,680
)
Accounts payable and accrued expenses
   
51,058
     
23,756
 
Accrued compensation, related party
   
31,250
     
-
 
Due to related parties
   
(525
)
   
-
 
Accrued interest, related party
   
9,452
     
-
 
Accrued interest
   
7,562
     
-
 
                 
Net cash used in operating activities
   
(294,907
)
   
(104,020
)
                 
CASH FLOWS FROM INVESTING ACTIVITIES
               
Payments to acquire equipment
   
(2,674
)
   
-
 
                 
Net cash used in investing activities
   
(2,674
)
   
-
 
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Proceeds from sale of common stock
   
-
     
529,322
 
Proceeds from related party note
   
150,000
     
-
 
                 
Net cash provided by financing activities
   
150,000
     
529,322
 
                 
Net increase in cash and cash equivalents
   
(147,581
)
   
425,302
 
                 
Cash and cash equivalents at beginning of period
   
208,821
     
-
 
                 
Cash and cash equivalents at end of period
 
$
61,240
   
$
425,302
 
                 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
               
Interest paid
 
$
-
   
$
-
 
Income taxes paid
 
$
-
   
$
-
 
                 
NON-CASH INVESTING AND FINANCING ACTIVITIES:
               
Stock issued to founder for intellectual property
 
$
-
   
$
500
 

See accompanying notes to these financial statements.
 

CLS HOLDINGS USA, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
August 31, 2015
(Unaudited)

Note 1 – Nature of Business and Significant Accounting Policies

Nature of Business

CLS Holdings USA, Inc. (the “Company”) was originally incorporated as Adelt Design, Inc. (“Adelt”) on March 31, 2011 to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced operations.
 
On November 12, 2014, CLS Labs, Inc. (“CLS Labs”) acquired 10,000,000 shares, or 55.6%, of the outstanding shares of common stock of Adelt from its founder, Larry Adelt. On that date, Jeffrey Binder, the Chairman, President and Chief Executive Officer of CLS Labs, was appointed Chairman, President and Chief Executive Officer of the Company. On November 20, 2014, Adelt adopted amended and restated articles of incorporation, thereby changing its name to CLS Holdings USA, Inc. Effective December 10, 2014, the Company effected a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-0.625 (the “Reverse Split”), wherein 0.625 shares of the Company’s common stock were issued in exchange for each share of common stock issued and outstanding. As a result, 6,250,000 shares of the Company’s common stock were issued to CLS Labs in exchange for the 10,000,000 shares that it owned by virtue of the above-referenced purchase from Larry Adelt.

On April 29, 2015, the Company, CLS Labs and CLS Merger Inc., a Nevada corporation and wholly owned subsidiary of CLS Holdings, entered into an Agreement and Plan of Merger (the “Merger Agreement”) and completed a merger, whereby CLS Merger Inc. merged with and into CLS Labs, with CLS Labs remaining as the surviving entity (the “Merger”). Upon the consummation of the Merger, the shares of the common stock of CLS Holdings owned by CLS Labs were extinguished and the stockholders of the Company were issued an aggregate of 15,000,000 (post Reverse Split) shares of common stock in CLS Holdings in exchange for their shares of common stock in CLS Labs. As a result of the Merger, the Company acquired the business of CLS Labs and abandoned its previous business.
 
The Company has a proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. These concentrates may be ingested in a number of ways, including through vaporization via electronic cigarettes (“e-cigarettes”), and used for a variety of pharmaceutical and other purposes. Internal testing of this extraction method and conversion process has revealed that it produces a cleaner, higher quality product and a significantly higher yield than the cannabinoid extraction processes currently existing in the marketplace. The Company has not commercialized its proprietary process or otherwise earned any revenues.  The Company plans to generate revenues through licensing, fee-for-service and joint venture arrangements related to its proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into saleable concentrates.

The Company has adopted a fiscal year end of May 31st.

Basis of Presentation

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in US dollars.

Principals of Consolidation

The accompanying consolidated financial statements include the accounts of CLS Holdings USA, Inc., and its wholly owned operating subsidiaries, CLS Labs, Inc. and CLS Labs Colorado, Inc.  All material intercompany transactions have been eliminated upon consolidation of these entities.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents.  The Company had cash and cash equivalents of $61,240 and $208,821 as of August 31, 2015 and May 31, 2015, respectively.

Property, Plant and Equipment

Property and equipment is recorded at the lower of cost or estimated net recoverable amount, and is depreciated using the straight-line method over the estimated useful lives.  Computer equipment is being depreciated over a three year period.

Concentrations of Credit Risk

The Company maintains its cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. The Company incurred no advertising and marketing costs for the three months ended August 31, 2015 and 2014.

Research and Development

Research and development expenses are charged to operations as incurred. The Company incurred no research and development costs for the three months ended August 31, 2015 and 2014, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the establishment of deferred tax assets and liabilities for the temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided to the extent deferred tax assets may not be recoverable after consideration of the future reversal of deferred tax liabilities, tax planning strategies, and projected future taxable income.
 
Fair Value of Financial Instruments

Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis.

Revenue Recognition

For revenue from product sales, the Company recognizes revenue using four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required.

The Company has not generated revenue to date.
 

Basic and Diluted Loss Per Share

Basic net earnings per share is based on the weighted average number of shares outstanding during the period, while fully-diluted net earnings per share is based on the weighted average number of shares of common stock and potentially dilutive securities assumed to be outstanding during the period using the treasury stock method. Potentially dilutive securities consist of options and warrants to purchase common stock, and convertible debt. Basic and diluted net loss per share is computed based on the weighted average number of shares of common stock outstanding during the period.
 
The Company uses the treasury stock method to calculate the impact of outstanding stock options and warrants. Stock options and warrants for which the exercise price exceeds the average market price over the period have an anti-dilutive effect on earnings per common share and, accordingly, are excluded from the calculation.

A net loss causes all outstanding stock options and warrants to be antidilutive. As a result, the basic and dilutive losses per common share are the same for the three months ended August, 31, 2015 and 2014.

Commitments and Contingencies
 
Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur.  The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment.  In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
 
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements.  If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
 
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

Recent Accounting Pronouncements
 
In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“this Update”) as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). The Board received feedback that having different balance sheet presentation requirements for debt issuance costs and debt discount and premium creates unnecessary complexity. Recognizing debt issuance costs as a deferred charge (that is, an asset) also is different from the guidance in International Financial Reporting Standards (IFRS), which requires that transaction costs be deducted from the carrying value of the financial liability and not recorded as separate assets. Additionally, the requirement to recognize debt issuance costs as deferred charges conflicts with the guidance in FASB Concepts Statement No. 6, Elements of Financial Statements, which states that debt issuance costs are similar to debt discounts and in effect reduce the proceeds of borrowing, thereby increasing the effective interest rate. Concepts Statement 6 further states that debt issuance costs cannot be an asset because they provide no future economic benefit. To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. For public business entities, the amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. The Company is currently evaluating the effects of adopting this ASU, if it is deemed to be applicable.

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed consolidated financial statements.
 
 
Note 2 – Going Concern

As shown in the accompanying financial statements, the Company has incurred net losses from operations resulting in an accumulated deficit of $1,992,099 as of August 31, 2015. Further losses are anticipated in the development of its business raising substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with loans and/or the proceeds from the sale of securities. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. 

Note 3 – Merger with CLS Labs

On April 29, 2015, the Company, CLS Labs and CLS Merger, Inc., a Nevada corporation and wholly owned subsidiary of the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”) and completed a merger, whereby CLS Merger, Inc. merged with and into CLS Labs, with CLS Labs remaining as the surviving entity (the “Merger”). Upon the consummation of the Merger, the shares of the common stock of CLS Holdings owned by CLS Labs were extinguished and the stockholders of CLS Labs were issued an aggregate of 15,000,000 (post Reverse Split) shares of common stock in the Company in exchange for their shares of common stock in CLS Labs. As a result of the Merger, the Company acquired the business of CLS Labs and abandoned its previous business.

For financial reporting purposes, the Merger represents a capital transaction of CLS Labs or a “reverse merger” rather than a business combination, because the sellers of CLS Labs controlled the Company immediately following the completion of the Merger. As such, CLS Labs is deemed to be the accounting acquirer in the transaction and, consequently, the transaction is being treated as a recapitalization of CLS Labs.  Accordingly, the assets and liabilities and the historical operations reflected in the Company’s ongoing financial statements are those of CLS Labs and are recorded at the historical cost basis of CLS Labs. The Company’s assets, liabilities and results of operations have been consolidated with the assets, liabilities and results of operations of CLS Labs after consummation of the Merger.  The Company’s historical capital accounts have been retroactively adjusted to reflect the equivalent number of shares issued by the Company in the Merger while CLS Labs’ historical retained earnings have been carried forward. The historical financial statements of the Company before the Merger will be replaced with the historical financial statements of CLS Labs before the Merger in all future filings with the Securities and Exchange Commission, or “SEC”.  The Merger is intended to be treated as a tax-free exchange under Section 368(b) of the Internal Revenue Code of 1986, as amended.

Pro Forma Results

The following tables set forth the unaudited pro forma results of the Company as if the acquisition of CLS Labs had taken place on the first day of the periods presented. These combined results are not necessarily indicative of the results that may have been achieved had the companies always been combined.
 
   
Three Months
 
   
Ended
 
   
August 31,
 
   
2014
 
Total revenue
 
$
-
 
Net loss attributable to CLS Holdings USA, Inc.
   
(128,657
)
Basic net income (loss) per common share
   
(0.01
)
Diluted net income (loss) per common share
   
(0.01
)
Weighted average shares - basic
   
15,000,000
 
Weighted average shares - diluted
   
15,000,000
 

Note 4 – Prepaid Expenses
 
Prepaid expenses consist of the following as of August 31, 2015 and May 31, 2015:

   
August 31,
   
May 31,
 
   
2015
   
2015
 
Prepaid legal fees
 
$
13,466
   
$
3,466
 
Prepaid consulting fees
   
1,000
     
28,334
 
Other prepaid fees
   
5,000
     
-
 
Total
 
$
19,466
   
$
31,800
 
 

Note 5 – Security Deposit

The company has a security deposit in the amount of $50,000 at August 31, 2015 and May 31, 2015.  This amount consists of a deposit to secure office and warehouse space.

Note 6 – Property, Plant and Equipment
 
Property, plant and equipment consist of the following at August 31, 2015 and May 31, 2015.

   
August 31,
   
May 31,
 
   
2015
   
2015
 
Computer equipment
 
$
2,674
   
$
-
 
     
2,674
     
-
 
Less: accumulated depreciation
   
(223
)
   
-
 
Net book value 
 
$
2,451
   
$
 -
 

Depreciation expense totaled $223 and $0 for the three months ended August 31, 2015 and 2014, respectively.

Note 7 – Intangible Assets

Intangible assets consist of the following at August 31, 2015 and May 31, 2015.
 
   
August 31,
   
May 31,
 
   
2015
   
2015
 
Domain name
 
$
2,158
   
$
2,158
 
 
  
 
2,158
     
2,158
 
Less: accumulated amortization
   
(72
)
   
-
 
Intangible assets, net
 
$
2,086
   
$
2,158
 

Total amortization expense charged to operations for the three months ended August 31, 2015 and 2014 was $72 and $0, respectively.  The domain name is being amortized over a period of 60 months.
 
Note 8 – Accounts Payable and Accrued Liabilities
 
Accounts payable and accrued liabilities of $196,082 and $145,024 at August 31, 2015 and May 31, 2015 consist of legal fees and other trade payables.
 
Note 9 – Notes Payable

Convertible Note Payable

On April 29, 2015, the Company issued a convertible note to an unaffiliated individual (the “Holder”) in the amount of $200,000 (the “Convertible Note”).  Interest accrues on the Convertible Note at a rate of 15% per annum. On the first anniversary of the Convertible Note, the Company shall pay all then accrued interest. Thereafter, the Company shall make eight (8) equal payments of principal together with accrued interest, quarterly in arrears, commencing on July 1, 2016 and continuing on the same day of each October, January, April and July thereafter until paid in full.  All outstanding principal and any accumulated unpaid interest thereon shall be due and payable on the third anniversary of note.

The Holder has the right but not the obligation to make additional loans to the Company (the "Subsequent Loans"), in tranches of $200,000 each, until the earlier of October 29, 2015 or until the Holder has made loans to Company that in the aggregate equal $1,000,000.  The Holder shall provide the Company with not less than five (5) business days’ notice of its desire to make a Subsequent Loan and the Company shall accept such Subsequent Loan and execute a promissory note, in the form of, and at the interest rate set forth in, the Convertible Note evidencing such Subsequent Loan.
 
 
At the Holder’s election, at any time prior to payment or prepayment of the Convertible Note in full, all principal and accrued interest under the Convertible Note may be converted in whole, but not in part, into shares of common stock of Company. For each dollar converted, the Holder shall receive two shares of common stock and a three-year warrant to purchase 1.33 shares (post Reverse Split) of common stock at $0.75 per share (post Reverse Split).

During the three months ended August 31, 2015 and 2014, the Company accrued interest in the amount of $7,562 and $0, respectively, on this note.  As of August 31, 2015 and May 31, 2015 the outstanding principal balance on the Convertible Note was $200,000 and the Company had accrued interest in the amount of $10,192 and $2,630, respectively on this note.

The Company calculated the fair value of the beneficial conversion features embedded in the Convertible Note via the intrinsic value method. The Company also calculates the fair value of the detachable warrants offered with the Convertible Note via the Black-Scholes valuation method.  The value of the conversion feature and the detachable warrants are considered discounts to the Convertible Note, to the extent the aggregate value of the warrants and conversion features did not exceed the face value thereof. These discounts were amortized to interest expense over the term of the Convertible Note.

The Company recorded a discount to the Convertible Note in the amount of $200,000 during the year ended May 31, 2015.  The discount was comprised of $100,000 related to the beneficial conversion feature embedded in the Convertible Note and $100,000 for the detachable warrants.  During the three months ended August 31, 2015 the Company amortized $16,666 of this discount to interest expense. As of August 31, 2015 and May 31, 2015, the Company had unamortized discounts on the Convertible Note in the amount of $177,778 and $194,444.

Koretsky and Binder Notes

During the year ended May 31, 2015, the Company borrowed $600,000 from Frank Koretsky, a director of the Company, to fund operations.  During the three months ended August 31, 2015 the Company borrowed an additional $130,000 from Mr. Koretsky to fund operations.  These loans are unsecured, due not less than one year after the date they were made, and bear interest at a rate of 6% per annum.  As of August 31, 2015 and May 31, 2015, the outstanding principal balance was $730,000 and $600,000 and the Company had accrued interest in the amount of $12,723 and $3,337. The balance of the loan terms have not yet been finalized.

During the three months ended August 31, 2015 the Company borrowed $20,000 from Jeffrey Binder, a director and officer of the Company, to fund operations.  This loan is unsecured, due not less than one year after the date of the loan, and bears interest at a rate of 6% per annum.  As of August 31, 2015 and May 31, 2015, the outstanding principal balance was $20,000 and $0 and the Company had accrued interest in the amount of $66 and $0. The balance of the loan terms have not yet been finalized.

Note 10 – Stockholders’ Equity
 
The Company’s authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share.    The Company had 20,060,003 and 20,000,003 shares (post Reverse Split) of common stock issued and outstanding as of August 31, 2015 and May 31, 2015, respectively.
 
On December 10, 2014, the Company effected a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1-for-0.625, wherein 0.625 shares of common stock were issued in exchange for each share of the Company’s common stock owned by the Company’s stockholders on December 1, 2014, the record date for the reverse stock split. As a result of the reverse stock split, 11,250,000 shares (post Reverse-Split) of common stock were outstanding as of December 10, 2014. The reverse stock split did not affect the number of authorized shares of the Company’s common stock. All share and per share information contained in the financial statements has been retroactively adjusted to reflect the reverse stock split.
 
The Company recorded imputed interest of $271 and $0 during the three months ended August 31, 2015 and 2014 on related party payables due to a director and officer of the Company.

On July 22, 2015, the Company agreed to issue 5,000 shares of common stock, valued at $5,750 based on the stock price at July 22, 2015, as part of a consulting agreement.  On August 26, 2015 the Company agreed to issue an additional 10,000 shares of common stock, valued at $12,700 based on the stock price on August 26, 2015, to extend the agreement.  As a result the Company had included $18,450 in stock payable on the accompanying balance sheet as of August 31, 2015.
 
 
On August 1, 2015, the Company and Alan Bonsett entered into a five-year employment agreement. Pursuant to the agreement, Mr. Bonsett commenced serving as the Company’s Chief Operating Officer on August 15, 2015. Mr. Bonsett is entitled to a one-time signing bonus of 250,000 (post Reverse Split) shares of restricted common stock of the Company, which will become fully vested one year from the effective date of the agreement.  As of August 31, 2015, no shares have been issued.  The Company valued the shares at $327,500 based on the stock price at August 3, 2015 and is amortizing them over the term of the employment agreement.  During the three months ended August 31, 2015 the Company recognized $27,292 in share based compensation, which is included in stock payable on the accompanying balance sheet.

On August 28, 2015, the Company issued 60,000 shares of common stock, valued at $45,000, to a consultant for services.  Of these shares, 50,000, valued at $37,500, were included in stock payable as of May 31, 2015.
 
Note 11 – Related Party Transactions
 
During the three months ended August 31, 2015 and 2014, the Company accrued related party payables in the amount of $0 and $0, respectively, for amounts due to officers and directors related to expenses paid on behalf of the Company.  As of August 31, 2015 and May 31, 2015 the Company had related party payables in the amount of $17,930 and $18,455.

During the three months ended August 31, 2015 and 2014, the Company recorded imputed interest of $271 and $0, respectively on related party payables due to a director and officer of the Company.

During the three months ended August 31, 2015 and 2014, the Company accrued compensation in the amount $31,250 and $0, respectively to Jeffrey Binder pursuant to his employment agreement.  Mr. Binder has deferred all salary since the commencement of the agreement.  At August 31, 2015 and May 31, 2015 total accrued compensation to Mr. Binder was $137,500 and $106,250, respectively.
 
On April 17, 2015, CLS Labs Colorado, Inc. (“CLS Labs Colorado”), a wholly owned subsidiary of the Company, loaned $500,000 (the “Note”) to Picture Rock Holdings, LLC, a Colorado limited liability company (“PRH”), to be used by PRH in connection with the financing of the building out, equipping, and development of a grow facility by PRH that will be operated by a licensed third-party marijuana grower.  Pursuant to the Note, as amended by the parties effective June 30, 2015, PRH will repay the principal due under the Note in twenty (20) equal quarterly installments of Twenty Five Thousand Dollars ($25,000) commencing three (3) months after a certificate of occupancy is issued with respect to the grow facility (the “CO Date”) and continuing until paid in full. Interest will accrue on the unpaid principal balance of the Note at the rate of twelve percent (12%) per annum and will be paid quarterly in arrears commencing on the CO Date and continuing until paid in full.  All remaining outstanding principal and any accumulated unpaid interest due under the Note will be due and payable on the five-year anniversary of the CO Date.  In the event of default as defined in the agreements related to the Note, all amounts under the Note shall become at once due and payable.  During the year ended May 31, 2015, the Company recorded an impairment related to the note receivable in the amount of $500,000.  This receivable is recorded on the balance sheet as of August 31, 2015 and May 31, 2015 in the amount of $0 and $0, net of allowance in the amount of $500,000.
 
On April 17, 2015, prior to Alan Bonsett’s appointment as Chief Operating Officer, the Company, through CLS Labs Colorado, entered into an arrangement with PRH (the “Colorado Arrangement”) to, among other things, (i) license its proprietary technology, methods and processes to PRH in Colorado in exchange for a fee; (ii) sub-lease warehouse and office space in Denver, Colorado to PRH where PRH can grow, extract and process cannabis and other plant products in exchange for lease payments totaling an aggregate of $1,067,067 over a seventy-two (72) month term; (iii) build a processing facility and lease such facility, including equipment, to PRH in exchange for a monthly fee; and (iv) loan $500,000 to PRH to be used by PRH in connection with its financing of the building out, equipping, and development of a marijuana grow facility. Mr. Bonsett, as an owner of PRH, will indirectly receive the benefits of the Colorado Arrangement.  Because construction of the Grow Facility is not yet complete, the business to be operated by PRH pursuant to the Colorado Arrangement has not yet produced revenues.

Koretsky Notes

During the year ended May 31, 2015, the Company borrowed $600,000 from Frank Koretsky, a director of the Company, to fund operations.  During the three months ended August 31, 2015 the Company borrowed an additional $130,000 from Mr. Koretsky to fund operations.  These loans are unsecured, due not less than one year after the date they were made, and bear interest at a rate of 6% per annum.  As of August 31, 2015 and May 31, 2015, the outstanding principal balance was $730,000 and $600,000 and the Company had accrued interest in the amount of $12,723 and $3,337. The balance of the loan terms have not yet been finalized.
 

Binder Note Payable
 
During the three months ended August 31, 2015 the Company borrowed $20,000 from Jeffrey Binder, a director and officer of the Company, to fund operations.  This loan is unsecured, due not less than one year after the date of the loan, and bears interest at a rate of 6% per annum.  As of August 31, 2015 and May 31, 2015, the outstanding principal balance was $20,000 and $0 and the Company had accrued interest in the amount of $66 and $0. The balance of the loan terms have not yet been finalized.

Note 12 – Commitment and Contingencies
 
The Company, through CLS Labs Colorado, leases 42,392 square feet of warehouse and office space (the “Leased Space”) in a building located on 1.92 acres in Denver Colorado. CLS Labs Colorado subleases the Leased Space to Picture Rock Holdings, LLC as part of an arrangement whereby Picture Rock Holdings, LLC will conduct certain intended activities, including growing, extraction, conversion, assembly and packaging of cannabis and other plant materials, as permitted by and in compliance with state, city and local laws, rules, ordinances and regulations.  Total expense for the lease was $44,461 and $0 for the three months ended August 31, 2015 and 2014.

Employment Agreements
 
CLS Labs and Jeffrey Binder entered into a five-year employment agreement effective October 1, 2014. Under the agreement, Mr. Binder serves as CLS Labs’ Chairman, President and Chief Executive Officer and is entitled to receive an annual salary of $150,000. Under the agreement, Mr. Binder is also entitled to receive a performance bonus equal to 2% of CLS Labs’ annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary), and annual stock options, exercisable at the fair market value of CLS Labs' common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million.  My Binder has deferred all salary since the commencement of the agreement.
 
Effective August 1, 2015, the Company and Alan Bonsett entered into a five-year employment agreement. Pursuant to the agreement, Mr. Bonsett commenced serving as the Company’s Chief Operating Officer on August 15, 2015. Under the agreement, Mr. Bonsett is entitled to receive an annual salary of $150,000. Further, he is entitled to receive a performance bonus equal to 2% of the Company’s annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary), and annual stock options, exercisable at the fair market value of the Company’s common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million. Additionally, Mr. Bonsett is entitled to a one-time signing bonus of 250,000 (post Reverse-Split) shares of restricted common stock of the Company, which will become fully vested one year from the effective date of the agreement. Mr. Bonsett, as an owner of PRH, will indirectly receive the benefits of the Colorado Arrangement, as discussed in Note 11. Because construction of the grow facility is not yet complete, the business to be operated by PRH pursuant to the Colorado Arrangement has not yet produced revenues.
  
Note 13 – Subsequent Events

We evaluated subsequent events after the balance sheet date through the date the financial statements were issued. We did not identify any additional material events or transactions occurring during this subsequent event reporting period that required further recognition or disclosure in these financial statements.
 
 

 
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

OVERVIEW AND OUTLOOK
 
The Company was incorporated on March 31, 2011 as Adelt Design, Inc. to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced.  On November 20, 2014, the Company changed its name to CLS Holdings USA, Inc.
 
On April 29, 2015 (the “Closing Date”), the Company, CLS Labs and the Merger Sub consummated the Merger, whereby the Merger Sub merged with and into CLS Labs, with CLS Labs remaining as the surviving entity. As a result of the Merger, we acquired the business of CLS Labs and abandoned our previous business. As such, only the financial statements of CLS Labs are included in this current report.
 
CLS Labs was originally incorporated in the state of Nevada on May 1, 2014 under the name RJF Labs, Inc. before changing its name to CLS Labs, Inc. on October 24, 2014. It was formed to commercialize a proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. These concentrates may be ingested in a number of ways, including through vaporization via electronic cigarettes (“e-cigarettes”), and used for a variety of pharmaceutical and other purposes. Testing in conjunction with two Colorado growers of this extraction method and conversion process has revealed that it produces a cleaner, higher quality product and a significantly higher yield than the cannabinoid extraction processes currently existing in the marketplace.

On April 17, 2015, CLS Labs took its first step toward commercializing its proprietary methods and processes by entering into an arrangement (the “Colorado Arrangement”), through its wholly owned subsidiary, CLS Labs Colorado, with certain Colorado entities, including Picture Rock Holdings, LLC. CLS Labs had not otherwise commercialized its proprietary process and had not earned any revenues prior to the Merger.

We intend to generate revenue through (i) the licensing of our proprietary methods and processes to others, as in the Colorado Arrangement, (ii) the processing of cannabis for others, and (iii) the purchase of cannabis and the processing and sale of cannabis-related products.  We plan to accomplish this through the creation of joint ventures, through licensing agreements, and through fee-for-service arrangements with growers and dispensaries of cannabis products. We believe that we can establish a position as one of the premier cannabinoid extraction and processing companies in the industry. Assuming we do so, we then intend to explore the creation of our own brand of concentrates for consumer use, which we would sell wholesale to cannabis dispensaries. We believe that we can create a “gold standard” national brand by standardizing the testing, compliance and labeling of our products in an industry currently comprised of small, local businesses with erratic and unreliable product quality, testing practices and labeling. We also plan to offer consulting services through a consulting subsidiary, Cannabis Life Sciences Consulting, LLC (“CLS Consulting”), which will generate revenue by providing consulting services to cannabis-related businesses, including growers, dispensaries and laboratories, and driving business to our processing facilities.

The Company had a net loss of $476,512 for the three months ended August 31, 2015, resulting in an accumulated deficit as of August 31, 2015 of $1,992,099. These conditions raise substantial doubt about our ability to continue as a going concern.
 
Results of Operations for the Three Months Ended August 31, 2015 and 2014

Revenues

The Company had no revenues during the three month periods ended August 31, 2015 and 2014.

General and administrative expenses

General and administrative expenses increased $90,387 or approximately 96% to $184,407 during the three months ended August 31, 2015 compared to $94,020 for the three month ended August 31, 2014.  General and administrative expenses consisted primarily of general office expenses, travel costs, rent expense, bank charges and payroll expenses.  We expect general and administrative expenses to increase in future periods as we implement our business plan and operations expand.

Professional fees

Professional fees increased $230,465, or approximately 819%, to $258,154 during the three months ended August 31, 2015 compared to $28,076 for the three months ended August 31, 2014.  This increase was due primarily to the payment of $160,284 in fees for consulting and investor relations services pursuant to consulting agreements and $74,419 in legal fees. We expect professional fees to increase in future periods as our business grows.

 
Interest expense

Interest expense for the three months ended August 31, 2015 was $33,951 compared to $0 for the three months ended August 31, 2014.  Interest expense consists of $271 of imputed interest, $17,014 of interest on debt and $16,666 of amortization of debt discounts on notes payable.
 
Net loss

For the reasons above, the Company had a net loss for the three months ended August 31, 2015 of $476,512 which is an increase in loss of ($354,416) or approximately 290% compared to a net loss of $122,096 during the three months ended August 31, 2014.

Liquidity and Capital Resources

The following table summarizes total current assets, liabilities and working capital at August 31, 2015 compared to May 31, 2015.
 
 
  
August 31,
2015
 
  
May 31,
2015
 
Current Assets
  
$
80,706
  
  
$
240,621
  
Current Liabilities
  
$
1,124,493
  
  
$
875,696
  
Working Capital (Deficit)
  
$
(1,043,787
)  
  
$
(635,075
 
 
At August 31, 2015 and May 31, 2015, the Company had a working capital deficit of $1,043,787 and $635,075, respectively. This working capital deficit occurred primarily because we had not yet commenced earning revenues at August 31, 2015.  We anticipate that we will commence earning revenues by the second quarter of 2016.  During the three months ended August 31, 2015, we obtained loans to cover operating expenses and expenses related to the Merger and the Colorado Arrangement.  This deficit will likely continue to increase until we begin earning revenues but should not be viewed as an indicator of our future performance once we commence earning revenues. We have operated at a loss since inception. 

To fund operations during the three months ended August 31, 2015, we borrowed $20,000 from Jeffrey Binder, an officer and director of the Company, and $130,000 from Frank Koretsky, a director of the Company.  These loans are unsecured, due not less than one year after the date they were made, and bear interest at a rate of 6% per annum.  The balance of the loan terms have not yet been finalized.
 
Over the next twelve months we will require significant additional capital to cover our projected cash flow deficits due to the Colorado Arrangement and related agreements, the repayment of the Convertible Loan and the loans from Jeffrey Binder and Frank Koretsky, the implementation of our business plan, and the development of alternative revenue sources.  Additionally, we anticipate that we will devote resources to research and development related to the refinement of our proprietary methods and processes and development of new products. We estimate research and development costs of between $50,000 and $100,000 during the next 12 months.  Finally, during the next 9-15 months, we plan to construct and open two to three processing facilities for use either by a licensee or by us directly.  We anticipate that the build out and opening of each processing facility will require between $1,000,000 and $3,000,000 in capital, with additional capital required for liquidity to cover personnel, equipment, and other operating expenses with respect to each opened facility.
 
We currently have two employees, Jeffrey Binder, who serves as the Chairman, President and Chief Executive Officer of the Company; and Alan Bonsett, who serves as the Chief Operating Officer of the Company.   In an effort to assist us conserve cash, Mr. Binder has deferred all of his salary (approximately $137,500 as of August 31, 2015) to date.  Mr. Bonsett is entitled to a one-time signing bonus of 250,000 (post Reverse Split) shares of restricted common stock of the Company, which will become fully vested one year from the effective date of his employment agreement.  As of August 31, 2015, no shares had been issued.  The Company valued the shares at $327,500 and is amortizing them over the term of the employment agreement.  During the three months ended August 31, 2015 we recognized $27,292 in share based compensation, which is included in stock payable on the accompanying balance sheet.

We also utilize the services of an outside investor relations consultant.  We pay the consultant a monthly fee of $6,000 at the beginning of each month and have awarded the consultant 120,000 shares of restricted common stock that vest at a rate of 10,000 shares per month.  During the three ended May 31, 2015, we paid $12,000 to the consultant and 10,000 (post Reverse Split) shares vested.  We terminated the consulting agreement during the three months ended August 31, 2015 and issued the 60,000 shares common stock that had vested, of which 50,000 shares with a value of $37,500 were included in stock payable as of May 31, 2015.
 

During the three months ended August 31, 2015, we entered into a separate investor relations agreement with a consultant for a 30 day period.  We paid the consultant $15,000 and agreed to issue 5,000 shares of the Company’s restricted common stock.  Prior to the expiration date of the consulting agreement the Company extended the agreement for an additional 34 day period.  As compensation for the extension, we paid the consultant $20,000 and agreed to issue 10,000 shares of the Company’s restricted common stock.  We valued the 15,000 shares of common stock at $18,450.  As of August 31, 2015, we had not yet issued the 15,000 shares, which are included in stock payable on the accompanying balance sheets.

We plan to hire a Chief Financial Officer, administrative staff, a lab manager and a consultant, for a total of approximately six employees.  In addition, each processing facility will require six to eight employees, depending upon the size of the facility. We also intend to use the services of independent consultants and contractors, such as our investor relations consultant, to perform various professional services when appropriate. We believe the use of third-party service providers may enhance our ability to control general and administrative expenses and operate efficiently as we implement our business plan. Currently, there are no organized labor agreements or union agreements and we do not anticipate any in the future. We are unable to estimate the cost of additional personnel at this time, but we expect such costs to be significant.
 
We do not currently have the capital necessary to meet our liquidity needs, fund our capital requirements or implement our business plan. We intend to fund our cash flow and capital requirements during the next year from the proceeds of the sale of our common stock, by obtaining additional loans and with cash generated through operations in connection with the Colorado Arrangement. There can be no assurance that we will be able to meet our needs, however, as we have not yet received any commitments for the purchase of our equity securities or for additional loans.  Further, although we anticipate that we will begin receiving payments pursuant to the Licensing Agreement and Equipment Lease during the second quarter of 2016, the Colorado Arrangement has not generated revenue to date and, as described above, there can be no assurance that it will ever generate sufficient cash to repay the $500,000 loan from CLS Labs Colorado or to meet PRH's obligations under the Licensing Agreement or Equipment Lease. We anticipate that we will incur operating losses during the next twelve months.

Going concern
 
Our financial statements were prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. We have incurred continuous losses from operations since inception, have an accumulated deficit of $1,992,099 and had a working capital deficit of $1,043,787 at August 31, 2015. In addition, we do not currently have the cash resources to meet our operating commitments during the next twelve months. Our ability to continue as a going concern must be considered in light of the problems, expenses, and complications frequently encountered by developmental stage companies.

Our ability to continue as a going concern is dependent on our ability to generate sufficient cash from operations to meet our cash needs, to borrow capital and to sell equity to support the opening of processing facilities and to finance ongoing operations. There can be no assurance, however, that we will be successful in our efforts to raise additional debt or equity capital and/or that our cash generated by our future operations will be adequate to meet our needs. These factors, among others, indicate that we may be unable to continue as a going concern for a reasonable period of time.
 
Summary of product and research and development that we will perform for the term of our plan.

We are not anticipating significant research and development expenditures in the near future.
 
Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that are material to investors.
 
 
Recently Issued Accounting Standards 

In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“this Update”) as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). The Board received feedback that having different balance sheet presentation requirements for debt issuance costs and debt discount and premium creates unnecessary complexity. Recognizing debt issuance costs as a deferred charge (that is, an asset) also is different from the guidance in International Financial Reporting Standards (IFRS), which requires that transaction costs be deducted from the carrying value of the financial liability and not recorded as separate assets. Additionally, the requirement to recognize debt issuance costs as deferred charges conflicts with the guidance in FASB Concepts Statement No. 6, Elements of Financial Statements, which states that debt issuance costs are similar to debt discounts and in effect reduce the proceeds of borrowing, thereby increasing the effective interest rate. Concepts Statement 6 further states that debt issuance costs cannot be an asset because they provide no future economic benefit. To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. For public business entities, the amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. The Company is currently evaluating the effects of adopting this ASU, if it is deemed to be applicable.

Management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed consolidated financial statements.
 
Item 3. Quantitative and Qualitative Disclosure About Market Risk.

This item is not applicable as we are currently considered a smaller reporting company.
 
Item 4. Controls and Procedures.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit pursuant to the requirements of the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, among other things, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

Jeffrey Binder, our Chief Executive Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report.  Based on the evaluation, Mr. Binder concluded that our disclosure controls and procedures are not effective in timely alerting him to material information relating to us that is required to be included in our periodic SEC filings and ensuring that information required to be disclosed by us in the reports we file or submit under the Act is accumulated and communicated to our management, including our chief financial officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure, for the following reasons:
 
 
·
We do not have an independent board of directors or audit committee or adequate segregation of duties; and
 
 
·
We do not have an independent body to oversee our internal controls over financial reporting and lack segregation of duties due to our limited resources.
 
We plan to rectify these weaknesses by implementing an independent board of directors and hiring additional accounting personnel once we have additional resources to do so.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

We know of no material pending legal proceedings to which the Company is a party or of which any of its property is the subject. In addition, we do not know of any such proceedings contemplated by any governmental authorities.

Item 1A. Risk Factors.
 
This item is not applicable as we are currently considered a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On July 22, 2015, pursuant to a consulting agreement, the Company agreed to issue 5,000 shares of common stock, valued at $5,750, to Wall Street Buy Sell Hold in exchange for consulting services.

On August 26, 2015, pursuant to an amendment to the consulting agreement between the parties, the Company agreed to issue an additional 10,000 shares of common stock, valued at $12,700, to Wall Street Buy Sell Hold in exchange for consulting services.

On August 28, 2015, pursuant to a consulting agreement, the Company issued 60,000 shares of common stock, valued at $45,000, to Stratcon Partners, LLC in exchange for consulting services.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.
 
31.1  Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
   
31.2  Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
   
32.1 Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
   
101.INS XBRL Instance Document
   
101.SCH XBRL Taxonomy Extension Schema
   
101.CAL XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF XBRL Taxonomy Extension Definition Linkbase
   
101.LAB XBRL Taxonomy Extension Label Linkbase
   
101.PRE XBRL Taxonomy Extension Presentation Linkbase
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
CLS HOLDINGS USA, INC.
 
       
Date: October 13, 2015
By:
/s/ Jeffrey I. Binder
 
   
Jeffrey I. Binder
 
   
Chairman, President and Chief Executive Officer
(Principal Executive Officer and Principal Financial Officer)
 

 
 

 
 
 
20